Clinical TrialsThe MIRACLE design positions the company to move forward quickly to open sites in Europe and the Middle East, treat the first subject, as well as open sites in the U.S.
FundingThe company was able to successfully complete two transactions under more favorable terms, including a warrant inducement transaction and a registered direct offering, which combined raised $9.3M.
Regulatory ApprovalsAnnamycin currently has Fast Track and Orphan Drug Designation from the FDA for the treatment of R/R AML, increasing potential to accelerate its timeline for approval.